Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
1.680
+0.020 (1.20%)
Dec 20, 2024, 4:00 PM EST - Market closed
Fate Therapeutics Employees
Fate Therapeutics had 181 employees as of December 31, 2023. The number of employees decreased by 370 or -67.15% compared to the previous year.
Employees
181
Change (1Y)
-370
Growth (1Y)
-67.15%
Revenue / Employee
$74,293
Profits / Employee
-$984,702
Market Cap
191.34M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Amarin Corporation | 275 |
Molecular Partners AG | 168 |
Gossamer Bio | 135 |
Stereotaxis | 122 |
Perspective Therapeutics | 119 |
MediWound | 100 |
XBiotech | 82 |
Cybin | 50 |
FATE News
- 12 days ago - Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus - GlobeNewsWire
- 18 days ago - Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 22 days ago - Fate Therapeutics Announces Leadership Transition - GlobeNewsWire
- 25 days ago - Fate Therapeutics to Present at Upcoming December Investor Conferences - GlobeNewsWire
- 4 weeks ago - Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options - Seeking Alpha
- 4 weeks ago - Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence - GlobeNewsWire
- 5 weeks ago - Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates - GlobeNewsWire
- 6 weeks ago - Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting - GlobeNewsWire